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While high-intensity focused ultrasound has been used for some time in the management of 
uterine fibroids, its effectiveness and safety in managing adenomyosis is less well established. 
A literature review was performed of all eligible reports using this modality as a treatment for 
adenomyosis. Relevant publications were obtained from the PubMed electronic database from 
inception through March 2016. Eleven articles, including information from 1,150 treatments and 
follow-up data from 990 patients, were reviewed. High-intensity focused ultrasound appears to 
be effective and safe in the management of symptomatic adenomyosis, and can be considered 
as an alternative uterine-sparing option for women with this condition. 
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Introduction
Uterine adenomyosis is a common gynecologic disorder of women of reproductive age. It is 
characterized by the presence of ectopic endometrial glands and stroma within the myometrium, 
resulting in uterine enlargement. It can be asymptomatic, but can give rise to significant symptoms, 
most commonly menorrhagia and dysmenorrhea [1]. The treatment for adenomyosis can be 
challenging. Historically, the standard of treatment has been hysterectomy. However, this is not always 
an acceptable option, especially for women who wish to maintain their fertility. Medical treatment 
mainly allows the control of symptoms, whereas uterine-sparing surgical techniques, such as the 
excision of adenomyotic foci or electrocoagulation of the involved myometrium, are associated with 
variable success and risk of recurrence [1,2]. Although uterine artery embolization has been used as 
a minimally invasive treatment option with some success, its impact on future fertility and pregnancy 
remains uncertain [1,3,4]. 
Recently, increasing attention has been paid to high-intensity focused ultrasound (HIFU) therapy for 
the management of adenomyosis [5,6]. It induces focal thermocoagulation of the adenomyotic lesions 
and has been shown to be a safe and effective treatment for adenomyosis [5,6]. Magnetic resonance 
(MR) imaging and, more recently, ultrasound (US) have been used to target and monitor the ablation 
process [5,7,8]. HIFU may also be able to provide an additional minimally invasive treatment option 
for premenopausal women with uterine adenomyosis. The purpose of this article was to review the 
background, clinical use, and treatment outcomes of HIFU in the treatment of adenomyosis. 
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Imaging-Guided HIFU
In 1942, Lynn et al. [9] introduced the use of an extracorporeal 
source of focused US energy to induce coagulative necrosis in 
targeted tissue without damaging surrounding and overlying vital 
structures. The principle of this HIFU therapy is to cause tissue 
ablation through heating, cavitation, and direct damage to tumor 
blood vessels, by focusing US energy at a targeted spot, with 
minimal damage to the surrounding tissues.
HIFU can be performed under the guidance of MR or US imaging 
in order to target and monitor the ablation process. MR imaging 
offers excellent anatomic resolution and temperature sensitivity 
during real-time treatment monitoring. The ExAblate device 
(Insightec, Tirat Carmel, Israel) is currently the only United States 
Food and Drug Administration (FDA)-approved MR-guided HIFU 
system. Another system, the Sonalleve (Philips Healthcare, Andover, 
MA, USA), has received Conformité Européene (CE) marking for 
fibroid treatment.
US-guided HIFU uses grayscale or echogenicity changes to 
determine the adequacy of ablation instead of temperature-
mapping changes, as in MR-guided HIFU. The JC HIFU system 
(Chongqing Haifu Technology, Chongqing, China) (Fig. 1) has 
been installed at Queen Mary Hospital since 2006, mainly for the 
treatment of hepatocellular carcinoma [10]; since 2011, the ablation 
of symptomatic uterine fibroids has also been performed [7,8]. 
As described in a previous review of fibroid management [7], this 
HIFU system consists of a real-time 3.5-MHz diagnostic US scanner 
integrated into the center of a 12-cm in diameter, 15-cm in focal 
length, 0.8-MHz therapeutic US transducer (Fig. 2). In addition to 
the US system, it contains a 6-direction therapeutic planning system, 
a degassed water circulation system, and a master control 
computer unit. The system can attain an acoustic output power of 
up to 400 W, and the linear motion deviation of the therapeutic 
device is ±1 mm. During treatment, patients are placed in the prone 
position under intravenous conscious sedation. This enables minimal 
patient movement while the lower abdominal skin is in contact with 
the degassed water. The entirety of the lesion is divided into slices 
of 5 mm. The acoustic output power is set between 350 and 400 W, 
and with successive sweeps from the deep to the shallow region, 
the entire volume of the lesion is ablated [7]. Fig. 3 illustrates the 
MR images of a woman with extensive adenomyosis before and 3 
months after HIFU treatment. Other similar systems, including the 
HIFU-2001 (SJTU Suntec Industry, Shanghai, China), HIFUNIT9000 
(Shanghai A&S Science and Technology, Shanghai, China), and FEP-
BY Series (China Medical Technologies, Beijing, China) are also 
currently used clinically for the treatment of fibroids. However, none 
of these systems described have received FDA approval.
The selection criteria for HIFU therapy for adenomyosis vary 
depending on the experience of an individual center. The criteria used 
in most studies can be summarized as follows: (1) premenopausal 
women of over 18 years of age with no plans for future child-
bearing [11-16]; (2) significant symptoms related to adenomyosis 
[11-17]; (3) features of adenomyosis on MR imaging [11,13-16]; 
(4) adenomyotic lesions greater than 3 cm but less than 10 cm in 
diameter [11,14]; (5) no evidence of known or suspected extensive 
pelvic adhesions, such as a history of acute pelvic inflammatory 
disease, severe pelvic endometriosis, or lower abdominal surgery 
[12-18]; and (6) body weight of less than 100 kg [16] or abdominal 
wall thickness of less than 5 cm [17]. 
Treatment centers vary in their protocols for patient assessment 
Fig. 1. Ultrasound-guided high-intensity focused ultrasound 
system.
Fig. 2. Real-time diagnostic ultrasound scanner integrated into 
the center of the therapeutic ultrasound transducer. 
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and preparation. Pretreatment imaging to confirm the diagnosis and 
to establish the extent of adenomyosis is performed. Additionally, 
pretreatment planning is carried out with the patient lying prone 
on the treatment table, which mimics the treatment process and 
familiarizes the patient with the treatment. During the planning 
process, the path of sonication, depth of the target, proximity of the 
target to the sacrum, and the likelihood of the presence of a bowel 
loop along the path of sonication are evaluated [7].
Literature Review
A review of the literature published in English was obtained from 
the PubMed electronic database from inception through March 
2016, using the search words ‘‘adenomyosis’’ and “high-intensity 
focused ultrasound,” “HIFU,” or “focused ultrasound ablation,” 
supplemented by hand-searching the references of the relevant 
articles. The acceptability of the articles to be included in the 
review was decided by reading the articles’ abstracts and full text 
if necessary, and only those articles that evaluated the use of HIFU 
in the treatment of adenomyosis without associated fibroids and 
included complete interpretable information with relevant outcome 
data were reviewed. Ultimately, 11 articles were reviewed. The 
information that was retrieved from the eligible articles included 
the number of patients, treatment details, criteria for symptom 
assessment, volume of uteri and adenomyotic lesions, and related 
complications.  
Eleven articles were identified, including information from 1,150 
treatments and follow-up data from 990 patients [11-21]. Table 1 
summarizes the background information of each article. Of these 11 
articles, five were MR-guided and six were US-guided HIFU studies, 
reporting a total of 84 and 1,066 treatments with follow-up data, 
respectively. Two articles were excluded because their reported 
treatment(s) were likely duplicates of those reported in other articles 
[22,23]. Among the reviewed articles, seven were prospective cohort 
studies [11,12,14-16,18,21], three were retrospective reviews 
[13,17,20], and one was a case report [19]. All articles reported the 
degree of symptom improvement, but only four reported the degree 
of uterine volume or adenomyotic lesion reduction [11,12,14,17]. 
Treatment Outcomes
Table 2 presents details of the 10 studies that evaluated the 
improvement of menorrhagia; seven studies used the symptom 
severity score of a quality of life questionnaire specific to fibroids 
known as the Uterine Fibroid Symptom and Quality of Life 
questionnaire [24]; while three studies used the menstrual volume 
or menorrhagia scale, which was scored according to patients’ 
descriptions on a 5-point scale [15,21] or as described by Sharp 
et al. in 1995 [25]. The reported degree of menorrhagia reduction 
ranged from 12.4% to 33.3%, 25.3% to 80.8%, 16.4% to 52.4%, 
24.9% to 66.4%, 44.0%, and 44.8% at 1-, 3-, 6-, 12-, 18-, and 
24-month follow-ups, respectively (Table 2). 
The reduction of dysmenorrhea, as determined based on the 
menstrual pain score using a visual analog scale, was evaluated in 
Fig. 3. Magnetic resonance (MR) images from a 47-year-old woman with adenomyosis.
A. Pretreatment MR image shows extensive adenomyosis involving mostly the fundal and anterior uterine wall (arrows). B. MR image (with 
contrast) 3 months after treatment shows a well-defined hypoperfused area (arrows) as the result of focused ultrasound ablation.  
A B
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seven studies (Table 3); all showed a reduction of dysmenorrhea 
at 3 months (range, 25.0% to 83.3%), 6 months (range, 44.7% to 
100%), 12 months (range, 64.0% to 72.1%), 18 months (54.2%), 
and 24 months (56.0%).
Five studies reported the degree of uterine volume reduction 
after HIFU therapy, with values ranging from 12.7% to 54.0% over 
follow-up periods of 1 to 12 months (Table 4). However, only two 
articles reported the degree of reduction in adenomyotic lesions 
over 12 months (Table 4). The nonperfused volume, which is the 
percentage of the uterine volume ablated and shown as a non-
enhancing area on contrast-enhanced T1-weighed MR imaging after 
the treatment, has been suggested to be associated with the degree 
of subsequent symptom improvement. This indicator was reported 
in seven studies, with mean values ranging from 24.4% to 62.5% 
[11-16,19]. However, a study that reported a range of 5% to 99% 
was excluded [21]. 
Treatment Data
Table 5 shows the treatment data, including treatment and 
Table 2. Improvement of menorrhagia after high-intensity focused ultrasound for adenomyosis
Study
Reduction in menorrhagia (%)a)
1 3 6 12 18 24
Magnetic resonance-guided
　Ferrari et al. [18], 2016 - - - 66.4 - -
　Fan et al. [11], 2012 12.4 25.3 16.4 24.9 - -
　Polina et al. [19], 2012 - 31.6 47.4 - - -
　Kim et al. [20], 2011 - 25.9 40.7 - - -
　Fukunishi et al. [12], 2008 33.3 53.5 44.8 - - -
Ultrasound-guided
　Lee et al. [17], 2015 - 55.6 52.4 58 - -
　Shui et al. [21], 2015 -   44.8b) - 48.3b) - 44.8b)
　Long et al. [14], 2015 - 32.9 50.4 64.7 - -
　Zhou et al. [15], 2011 -   48.0b) - - 44.0b) -
　Wang et al. [16], 2009 - 57.0-80.8b, c) - - -
a)Months after treatment, based on the symptom severity score of the Uterine Fibroid Symptom and Quality of Life questionnaire, unless otherwise specified. b)Based on 
menstrual volume/menorrhagia score. c)Varied depending on power output (290-420 W).
Table 1. Summary of studies of high-intensity focused ultrasound for adenomyosis
Study City, country
High-intensity focused 
ultrasound system
No. of treatments 
No. of patients who 
completed follow-up
Duration of 
follow-up (mo)
Magnetic resonance-guided 
　Ferrari et al. [18], 2016 L' Aquila, Italy ExAblatea) 18 18 12
　Fan et al. [11], 2012 Chongqing, China JM15100b) 10 10 12
　Polina et al. [19], 2012 Andhra Pradesh, India ExAblatea) 1 1 6
　Kim et al. [20], 2011 Gyeonggi-do, South Korea ExAblatea) 35 35 6
　Fukunishi et al. [12], 2008 Kobe, Japan ExAblatea) 20 20 6
Ultrasound-guided 
　Liu et al. [13], 2016 Beijing, China JCb) 230 208 3
　Lee et al. [17], 2015 Incheon, South Korea JCb) 346 346 12
　Shui et al. [21], 2015 Chongqing and Sichuan, China JC200b) 350 224 24
　Long et al. [14], 2015 Chongqing, China JC200b) 51 47 12
　Zhou et al. [15], 2011 Chongqing, China JCb) 77 69 18
　Wang et al. [16], 2009 Beijing, China JCb) 12 12 3
a)Insightec, Tirat Carmel, Israel. b)Chongqing Haifu Technology, Chongqing, China. 
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Table 3. Improvement of dysmenorrhea after high-intensity focused ultrasound for adenomyosis
Study
Reduction in dysmenorrhea (%)a)
3 6 12 18 24
Magnetic resonance-guided
　Polina et al. [19], 2012 60 100 - - -
　Kim et al. [20], 2011 30.6 44.7 - - -
Ultrasound-guided
　Liu et al. [13], 2016 61.8 - - - -
　Shui et al. [21], 2015 62 - 64 - 56
　Long et al. [14], 2015 28.8 53.5 72.1 - -
　Zhou et al. [15], 2011 56.3 - - 54.2 -
　Wang et al. [16], 2009 25.0-83.3b) - - - -
a)Months after treatment, based on menstrual pain score. b)Varied depending on power output (290-420 W).
Table 4. Volume reduction of the uterus or adenomyotic lesion after high-intensity focused ultrasound
Study
Reduction in uterine volume or adenomyotic lesion volume (%)a)
1 3 6 12
Magnetic resonance-guided
　Fan et al. [11], 2012 21.9 (11.9)a) 22.5 (28.3)a) 29.3 (40.2)a) 23.8 (29.1)a)
　Fukunishi et al. [12], 2008 - - 12.7 -
Ultrasound-guided
　Lee et al. [17], 2015 - 44 47 54
　Long et al. [14], 2015 - - - 22 (30.2)a)
a)Months after treatment.
Table 5. Treatment data
Study Treatment timea) Sonication timeb) Total exposure energy (J) Volume of uterus (cm3)
Volume of adenomyotic 
lesion (cm3)
Magnetic resonance-guided
　Fan et al. [11], 2012 114±48 
(42-192)
990.5±480.6 
(245.0-1,727.0)
299,019.5±154,636.0 272.0±99.2 
(148.8-440.0)
94.9±54.6 
(30.4-208.4)
　Polina et al. [19], 2012 110 NA 108,996 NA 91
　Kim et al. [20], 2011 150±40 NA NA 430±230 NA
　Fukunishi et al. [12], 2008 <180 NA 157,745.4c) 
(69,066.8-491,840.3)
445±296 
(95% CI, 307-584)
NA
Ultrasound-guided
　Liu et al. [13], 2016 64c) 
(IQR, 47-91) 
1,135c)  
(IQR, 769-1,561)
NA 274.4±174.8 
(47-1,390)
70.7±33.0 
(16-177)
　Lee et al. [17], 2015 82.3c) 1,049.4c) 363,556.6c) 264.1c) NA
　Shui et al. [21], 2015 103.8±59.4 
(11.0-247.0)
1,197.3±744.2 
(114-4,000)
454,016.2±282,200.6 
(43,228.8-1,516,800)
253.1±109.3 
(100.4-708.2)
66.2±48.6 
(4.2-373.3)
　Zhou et al. [15], 2011 <180 NAd) NAd) NAd) NA
　Wang et al. [16], 2009 NA (468-3,413) (138,000-1,432,000) NAd) NA
Values are presented as mean±standard deviation (range), unless otherwise specified.
NA, not available; CI, confidence interval; IQR, interquartile range.
a)Treatment time (in minutes) was defined as the time from the first sonication to the last sonication, except in the study by Fan et al. [11], in which it was defined as the time 
from the first magnetic resonance localization scan to the last sonication. b)Sonication time (in seconds) was defined as the time of ablation when energy was delivered to the 
target. c)Median value. d)Mean treatment time between 1,132 and 1,820 seconds, mean total exposure energy between 384,637 and 765,571 J, and mean uterine volume 
between 213 and 253 cm3; varied depending on power output (290-420 W). 
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sonication time, and the total exposure energy. The volume of 
the uteri and the adenomyotic lesions were also included when 
available for reference, as these values may have directly influenced 
the duration of treatment. Treatment time was generally defined as 
the time from the first sonication to last sonication, unless otherwise 
specified in the article, and sonication time referred to the time of 
ablation when energy was being delivered to the target.
Complications
Complications arising from HIFU in the treatment of adenomyosis 
were rare. Five of the 11 studies reported no adverse events or 
serious complications [11,16,18-20]. The complications reported in 
the other five studies are summarized in Table 6. The most common 
complication was vaginal discharge or bleeding (range, 2.6% to 
58.8%). Tissue burns, as the result of excessive power generated 
or accumulated in an incorrect target or in organs adjacent to 
the target, were uncommon. Skin burns, mostly of a mild degree, 
occurred in seven patients, and there were no reports of bowel 
or urinary bladder injury. The study carried out by Lee et al. [17] 
was excluded, as their safety data combined both fibroid and 
adenomyosis treatment.
Discussion
The management of uterine adenomyosis can be challenging, 
particularly in patients who wish to maintain their fertility [1]. 
While making treatment decisions, the age of the patients, severity 
of symptoms, desire for future fertility, and associated pelvic 
pathologies such as fibroids and endometriosis are important 
considerations. Various uterine-sparing interventions have been 
described in managing adenomyosis, including uterine artery 
embolization, myometrial or adenomyoma excision or reduction, or 
myometrial electrocoagulation [1,2]. However, insufficient properly 
designed trials have been conducted for adequate evidence to 
support one treatment over the other. 
HIFU has been shown to be effective and safe in the treatment 
of uterine fibroids [6-8]. However, in treating adenomyosis, the 
effectiveness of HIFU is less well established and therefore, in our 
center, this treatment modality is still considered investigational. 
Adenomyosis can be a cause of significant morbidity, and further 
work is needed to explore more effective and safe therapies. The 
findings from this review seem encouraging, as HIFU appears to be 
effective in relieving, at least in part, the symptoms of adenomyosis, 
including menorrhagia and dysmenorrhea over a period of 1-2 
years after treatment. This modality can be considered as an 
alternative option for women with adenomyosis who wish to 
preserve their uteri. However, as a fertility-sparing option, further 
evidence is certainly required to reassure clinicians and patients of 
the safety of this intervention if further pregnancy is desired. 
This review includes studies of both MR-guided and US-guided 
HIFU. Although the principle of therapy is similar in both techniques, 
it is unclear whether one type of image guidance has advantages 
over the other. There is no doubt that the guiding images obtained 
during MR-guided therapy are much better than those obtained 
during US-guided therapy, especially during intraoperative mapping 
of the adenomyotic lesion, but whether this leads to better and safer 
treatment outcomes remains uncertain. 
This review has limitations. The lack of primary data in most 
studies made it impossible to carry out comparative evaluations 
of certain important parameters, such as the degree of symptom 
relief, treatment time, and sonication time. Data combining both 
Table 6. Summary of complications
Complication Fukunishi et al. [12] Liu et al. [13] Shui et al. [21] Long et al. [14] Zhou et al. [15]
No. of patients 20 230 350 51 77
Leg pain, prolongeda) 1 (5) - - - -
Sacrococcygeal or buttock pain, prolongeda) 2 (10) - - 4 (7.8) 2 (2.6)
Abdominal pain, prolongeda) - - - 1 (1.9) 1 (1.3)
Lower limb or perineal numbness - 2 (0.8) 1 (0.3) 9 (17.6) 3 (3.9)
Skin burn - 2b) (0.8) 3b) (0.9) - 2b) (2.6)
Low grade fever - - 1 (0.3) - -
Vaginal discharge or bleeding - 6 (2.6) 27 (7.7) 30 (58.8) 10 (13.0)
Hematuria - - - - 2 (2.6)
Contact dermatitis to acoustic gel pad 1 (5) - - - -
Data are presented as number (%).
a)Lasted more than 7 days. b)Four of the seven patients had first-degree burns, and three of the seven patients had second-degree burns.
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fibroid and adenomyosis treatment rendered a study unsuitable for 
evaluation [17]. The cost of each modality was not evaluated. The 
definitions of certain complications were not provided, so it was 
difficult to make comparisons between studies. Additionally, it is 
unfortunate that we were not able to include a recent large review 
consisting of 9,988 cases, of which 2,549 were adenomyosis, in this 
study, as no symptom outcome data were reported [6]. Nevertheless, 
despite these shortcomings, the availability of HIFU is indicative 
of the potential of advancements in adenomyosis treatment, and 
awareness of this treatment modality will allow physicians to 
provide optimal care to their patients. 
Conclusion
HIFU appears to be effective and safe in the management of 
symptomatic adenomyosis, and can be considered as an alternative 
uterine-sparing option for women with this condition. 
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